Blood Reviews

Papers
(The H4-Index of Blood Reviews is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting247
Interplay between platelets and coagulation138
Targeting MCL-1 in hematologic malignancies: Rationale and progress124
Coagulation and anticoagulation in COVID-19121
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system116
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes106
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis94
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents78
The looming storm: Blood and cytokines in COVID-1962
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions57
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved57
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map52
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities50
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment49
A review of FLT3 inhibitors in acute myeloid leukemia48
Role of inflammation in the biology of myeloproliferative neoplasms48
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions45
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research45
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation42
Illness and prognostic understanding in patients with hematologic malignancies41
Discussing investigational AAV gene therapy with hemophilia patients: A guide38
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities38
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies38
Inherited thrombocytopenias: an updated guide for clinicians37
Current management strategies for polycythemia vera and essential thrombocythemia35
Current and emerging strategies for management of myelodysplastic syndromes33
Current state and next-generation CAR-T cells in multiple myeloma33
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer31
Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy30
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia29
Second primary malignancies in multiple myeloma: A review29
0.022540807723999